Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019
Do we need controlled clinical trials in pulmonary arterial hypertension? Source: Eur Respir J 2001; 17: 1-3 Year: 2001
Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018
Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013
Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018
Clinical trials in pulmonary arterial hypertension: what they tell us Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020
Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017
Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010
Biological quality control and core laboratory considerations for CPET in a clinical trial of ralinepag in patients with pulmonary arterial hypertension: ADVANCE CAPACITY Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021
Exercise training improves peak oxygen consumption and hemodynamics in patients with pulmonary hypertension – A prospective, randomized, controlled trial Source: International Congress 2016 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2016
Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Source: Eur Respir J 2007; 29: 432-434 Year: 2007
Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different? Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017 Year: 2017